Newer antiepileptic drugs in the treatment of status epilepticus: Impact on prognosis

Epilepsy and Behavior

Volumn 24, Issue 1, 2012, Pages 70-73

  Jaques, Léonore ^a   Rossetti, Andrea O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Lacosamide; Levetiracetam; Mortality; Outcome; Pregabalin; Topiramate

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; RETIGABINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PROGNOSIS; PROSPECTIVE STUDY; REFERENCE DATABASE; RETROSPECTIVE STUDY; SYMPTOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATUS EPILEPTICUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860676803     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.02.026     Document Type: Article

References (37)

1. Lowenstein D.H. Status epilepticus: an overview of the clinical problem. Epilepsia 1999, 40(Suppl. 1):S3-S8.
2. Lowenstein D.H., Alldredge B.K. Status epilepticus. N Engl J Med 1998, 338:970-976.
3. Shorvon S. The management of status epilepticus. J Neurol Neurosurg Psychiatry 2001, 70(Suppl. 2):II22-II27.
4. Meierkord H., Boon P., Engelsen B., et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010, 17:348-355.
5. Kwan P., Brodie M.J. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003, 60(Suppl. 4):S2-S12.
6. Alacqua M., Trifirò G., Spina E., et al. Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. Epilepsy Res 2009, 85:107-113.
7. Towne A.R., Garnett L.K., Waterhouse E.J., Morton L.D., DeLorenzo R.J. The use of topiramate in refractory status epilepticus. Neurology 2003, 60:332-334.
8. Rossetti A.O., Bromfield E.B. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 2006, 8:651-654.
9. Novy J., Rossetti A.O. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia 2010, 51:2207-2210.
10. Stojanova V., Rossetti A.O. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand 2012, 125:e7-e11.
11. Berning S., Boesebeck F., van Baalen A., Kellinghaus C. Intravenous levetiracetam as treatment for status epilepticus. J Neurol 2009, 256:1634-1642.
12. Rüegg S., Naegelin Y., Hardmeier M., Winkler D.T., Marsch S., Fuhr P. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008, 12:477-480.
13. Knake S., Gruener J., Hattemer K., et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008, 79:588-589.
14. Kellinghaus C., Berning S., Immisch I., et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011, 123:137-141.
15. Novy J., Logroscino G., Rossetti A.O. Refractory status epilepticus: a prospective observational study. Epilepsia 2010, 51:251-256.
16. Logroscino G., Hesdorffer D.C., Cascino G., Annegers J.F., Hauser W.A. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997, 38:1344-1349.
17. Towne A.R., Pellock J.M., Ko D., DeLorenzo R.J. Determinants of mortality in status epilepticus. Epilepsia 1994, 35:27-34.
18. Chin R.F.M., Neville B.G.R., Scott R.C. A systematic review of the epidemiology of status epilepticus. Eur J Neurol 2004, 11:800-810.
19. Claassen J., Lokin J.K., Fitzsimmons B.-F.M., Mendelsohn F.A., Mayer S.A. Predictors of functional disability and mortality after status epilepticus. Neurology 2002, 8(58):139-142.
20. Shneker B.F., Fountain N.B. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003, 61:1066-1073.
21. Rossetti A.O., Hurwitz S., Logroscino G., Bromfield E.B. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006, 77:611-615.
22. Rossetti A.O., Logroscino G., Milligan T.A., Michaelides C., Ruffieux C., Bromfield E.B. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008, 255:1561-1566.
23. Savica R., Beghi E., Mazzaglia G., et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol 2007, 14:1317-1321.
24. Pugh M.J.V., Van Cott A.C., Cramer J.A., et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology 2008, 70:2171-2178.
25. Hsia Y., Neubert A., Sturkenboom M.C.J.M., et al. Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia 2010, 51:789-796.
26. Beydoun A. Monotherapy trials of new antiepileptic drugs. Epilepsia 1997, 38(Suppl. 9):S21-S31.
27. Vazquez B. Monotherapy in epilepsy: role of the newer antiepileptic drugs. Arch Neurol 2004, 61:1361-1365.
28. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
29. Marson A.G., Al-Kharusi A.M., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015.
30. Tsai M.-H., Chuang Y.-C., Chang H.-W., et al. Factors predictive of outcome in patients with de novo status epilepticus. QJM 2009, 102:57-62.
31. Alvarez V., Januel J.-M., Burnand B., Rossetti A.O. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011, 52:1292-1296.
32. Trinka E., Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord 2009, 2:79-91.
33. Shorvon S. The treatment of status epilepticus. Curr Opin Neurol 2011, 24:165-170.
34. Swisher C.B., Doreswamy M., Gingrich K.J., Vredenburgh J.J., Kolls B.J. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. Neurocrit Care 2012, 16:109-113.
35. Stephen L.J., Forsyth M., Kelly K., Brodie M.J. Antiepileptic drug combinations-have newer agents altered clinical outcomes?. Epilepsy Res 2012, 98:194-198.
36. Rossetti A.O., Lowenstein D.H. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011, 10:922-930.
37. Shorvon S., Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011, 134:2802-2818.